Study characteristics and clinical data reporting resolution outcomes of monoclonal antibodies and one FMT infusion from the included studies
| Author, year of publication | Study design | Standard antibiotic therapy | Actoxumab+bezlotoxumab | FMT | Bezlotoxumab | Actoxumab |
| Method of administration (CDI resolved/total patients) | CDI resolved/total patients | CDI resolved/total patients | CDI resolved/total patients | CDI resolved/total patients | ||
| Van Nood et al, 201312 | Open-label RCT | Vanocomycin 500 mg orally four times daily for 14 days (7/26). | Vancomycin 500 mg orally four times daily for 4 days followed by FMT (13/16). | |||
| Cammarota et al, 20159 | Open-label RCT | Vancomycin 125 mg orally four times daily for 10 days followed by 125–500 mg/day every 2–3 days for 3 weeks (5/19). | Vacomycin 125 mg orallt four times daily for 3 days followed by FMT (13/20). | |||
| Hota et al, 201719 | Open-label RCT | Vancomycin 125 mg orally four times daily for 14 days, then 125 mg orally two times daily for 7 days, then 125 mg orally daily for 7 days, then 125 mg orally every second day for 7 days, then 125 mg orally every third day for 7 days (7/12). | Vancomycin 125 mg orally four times daily for 14 days followed by FMT after 48 hours (7/16). | |||
| Ng et al, 2017 (Abstract)21 | Open-label RCT | Vancomycin 500 mg orally four times daily for 10 days (10/15). | Vancomycin 500 mg orally four times daily followed by FMT (11/15). | |||
| Leav et al, 201020 | Phase II double-blinded RCT | Standard treatment course of vancomycin or metronidazole (14/17). | Standard treatment course of vancomycin or metronidazole followed by a single dose of 10 mg/kg IV of actoxumab (24/29). | |||
| Lowy et al, 201015 | Phase III double-blinded RCT | Standard treatment course of vancomycin or metronidazole (74/99). | Standard treatment course of vancomycin or metronidazole followed by a single dose 10 mg/kg IV of each actoxumab and bezlotoxumab (94/101). | |||
| Wilcox et al, 2017 (Modify 1)16 | Phase III double-blinded RCT | Standard treatment course of vancomycin, metronidazole or fidaxomicin for 10–14 days (286/395). | Standard treatment course of vancomycin, metronidazole or fidaxomicin followed by a single dose 10 mg/kg IV of each actoxumab and bezlotoxumab (322/383). | Standard treatment course of vancomycin, metronidazole or fidaxomicin followed by a single dose 10 mg/kg IV of bezlotoxumab (319/386). | Standard treatment course of vancomycin, metronidazole or fidaxomicin followed by a single dose 10 mg/kg IV of actoxumab (172/232). | |
| Wilcox et al 2017 (Modify 2)16 | Phase III double-blinded RCT | Standard treatment course of vancomycin, metronidazole or fidaxomicin for 10–14 days (281/378). | Standard treatment course of vancomycin, metronidazole or fidaxomicin followed by a single dose 10 mg/kg IV of each actoxumab and bezlotoxumab (332/390). | Standard treatment course of vancomycin, metronidazole or fidaxomicin followed by a single dose 10 mg/kg IV of bezlotoxumab (333/395). |
CDI, Clostridium difficile infection; FMT, faecal microbiota transplantation; IV, intravenous; RCT, randomised controlled trial.